Develop the Next Wave of Breakthroughs

Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Marketed
NUPLAZID® (pimavanserin)[1]	Parkinson's Disease Psychosis					
Pimavanserin*[2]	Alzheimer's Disease Psychosis					
Trofinetide[3†]	Rett Syndrome					
Pimavanserin*	Negative Symptoms of Schizophrenia					
ACP-044†	Postoperative and Osteoarthritis Pain					
ACP-319[4†]	Schizophrenia and Cognition in Alzheimer's					
Stoke Therapeutics Collaboration[5]	Multiple ASO Programs *(SYNGAP1, Rett, other)*					
Additional Preclinical Programs *(undisclosed)*						

[1] NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
[2] Acadia received a CRL for its sNDA for pimavanserin for the treatment of DRP. Acadia has resubmitted the sNDA for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.
[3] Acadia has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals.
[4] Acadia has an exclusive worldwide license to develop and commercialize ACP-319 and other M1 PAM program compounds from Vanderbilt University.
[5] Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases.
* Safety and Efficacy of NUPLAZID for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis and negative symptoms of schizophrenia have not been established or approved by the FDA.
† Trofinetide, ACP-044, and ACP-319 are investigational agents, and their safety and efficacy have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency.
Provided May 4, 2022 as part of an oral presentation and is qualified by such; contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.